Evidence map›Paper›PMID 35924153›Full record

ArticleFrontiers in oncology2022

Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer.

Liang Shi, Rui Duan, Qiong Jia, Wenyu Wu, Jianming Zhou, Shaohua Li, Hao Zhang, Xue Xue

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Liang ShiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Rui DuanDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Qiong JiaDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Wenyu WuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jianming ZhouDepartment of Nuclear Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Shaohua LiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Hao ZhangDepartment of Emergency, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Xue XueDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNAffiliated Hospital of Jiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Host immunity influences the impact of cancer therapy but the effect of immune status in radioiodine (RAI)-treated differentiated thyroid cancer (DTC) remains obscure. Here we investigated indoleamine 2,3-dioxygenase (IDO) activity as a biomarker of response to RAI in patients with distant metastatic DTC (dmDTC). Methods: Patients with dmDTC receiving RAI were evaluated for serum IDO activity (kynurenine and kynurenine:tryptophan ratio) at baseline and 3 months after RAI. The optimal cut-off value for these biomarkers to predict response was established by receiver operating characteristic analysis. The relationship between disease outcomes, overall survival (OS) and progression-free survival (PFS), and IDO activity levels was studied. Results: Higher baseline kynurenine:tryptophan ratio (>2.46) was correlated with poorer RAI response as well as shorter median PFS (45 mo versus not reached, Conclusions: Our results suggest that RAI also alters IDO activity in dmDTC patients. IDO activity could predict progression and survival outcomes for advanced dmDTC patients. Serum IDO biomarker levels could be used to select dmDTC likely to benefit from RAI therapy, although further studies are necessary.

Indexed as

3-dioxygenase (IDO)differentiated thyroid cancerimmune suppressionindoleamine 2predictive factorsradioiodine

Identifiers

PMID35924153
PMCPMC9339611
OpenAlexW4285731216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.